Carton1
Gemcitabine Injection, Powder, Lyophilized, For Solution
Product Images NDC 55111-686
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gemcitabine (NDC 55111-686). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Dr. Reddy's Laboratories Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Carton2
Gemcitabine is a medication that comes in injection form, and it's classified as a USP drug. No additional information can be obtained from this -generated text.*
Figure1
This seems to be a medical report with data on the progression-free probability, median progression-free survival, and survival time of patients with different types of cancer under treatment with different drugs such as Carboplatin and Gemciabios for varying periods of time. However, the information is not clear and complete enough to provide a more specific description.*
Figure2
Median Time to Documented Disease Progression with paclitaxel was 5.2 months and with gemcitabine for jacinth paclitaxel was 29 months. The Progression-Free Probability was calculated and represented with alphanumeric symbols. The study also revealed statistical significance with Log-rank p-value of less than 0.0001. The time to documented disease progression was illustrated through a graph with time in months on the x-axis and the number of patients on the y-axis.*
Figure3
This text appears to report the results of a clinical trial comparing two treatments, Gemcitabine/Cisplatin and Cisplatin alone, for an unspecified medical condition. The trial found that patients receiving Gemcitabine/Cisplatin had a median survival time of 9.0 months, while patients receiving only Cisplatin had a median survival time of 7.6 months. The statistical analysis showed a significant difference between the two groups in terms of survival, with a logrank p-value of 0.008 and a Wilcoxon p-value of 0.018. The text also includes a graph showing the survival probabilities for the two treatments over time.*
Figure4
Structure
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
